Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer - PubMed (original) (raw)

Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer

Katherine E Reeder-Hayes et al. Breast Cancer Res Treat. 2014 Jun.

Abstract

Endocrine therapy (ET) is the cornerstone of adjuvant therapy for hormone-receptor positive (HR+) breast cancer. The survival gap between African-American (AA) and white women with breast cancer is most pronounced in HR+ subtypes, and could be related to differences in ET use. The relationship between race and initiation of ET is not well defined. We investigated patterns of ET initiation by race in a diverse cohort of women covered by commercial health insurance. We identified 2,640 women with incident HR+ breast cancer in the North Carolina Central Cancer Registry whose records linked to commercial insurance claims using the Integrated Cancer Information and Surveillance System (ICISS) database. The sample included women age <65 years diagnosed with stage I-III HR+ cancers between 2004 and 2009. We used multivariate Poisson regression to examine the effect of race on likelihood of initiating ET. 14 % of women did not initiate ET within 12 months of diagnosis. AA women were 17 % less likely to initiate ET than whites (aRR 0.83, 95 % CI 0.74-0.93). When analyzed by subset, racial disparities persisted among women who received chemotherapy (aHR 0.67, 95 % CI 0.56-0.80) but not among women who did not receive chemotherapy (aHR 0.96, 95 % CI 0.76-1.21). AA women in our sample were less likely to initiate ET than whites, and this disparity was concentrated among chemotherapy-treated women. ET under-utilization may contribute to the racial survival gap in HR+ breast cancer, and represents an opportunity for intervention to reduce breast cancer disparities.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors have declared that they have no financial conflicts of interest.

Figures

Fig. 1

Fig. 1

Cohort diagram

Fig. 2

Fig. 2

Cumulative rates of endocrine therapy initiation by race at 12 months post-diagnosis among chemotherapy-treated women (panel a) and women who did not receive chemotherapy (panel b)

Similar articles

Cited by

References

    1. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40(8 Suppl):IV-19-25. doi: 10.1097/01.MLR.0000020934.40692.C0. - DOI - PubMed
    1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97(19):1407–1427. doi: 10.1093/jnci/dji289. - DOI - PubMed
    1. O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC. Intrinsic breast tumor subtypes, race, and long-term survival in the carolina breast cancer study. Clin Cancer Res. 2010;16(24):6100–6110. doi: 10.1158/1078-0432.CCR-10-1533. - DOI - PMC - PubMed
    1. Banerjee M, George J, Yee C, Hryniuk W, Schwartz K. Disentangling the effects of race on breast cancer treatment. Cancer. 2007;110(10):2169–2177. doi: 10.1002/cncr.23026. - DOI - PubMed
    1. Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat. 2005;89(1):47–54. doi: 10.1007/s10549-004-1470-1. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources